Welcome to our dedicated page for iBio SEC filings (Ticker: IBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on iBio's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into iBio's regulatory disclosures and financial reporting.
iBio, Inc. filed a Form 8-K describing new preclinical results for IBIO-610, an Activin E antibody candidate being studied for fat-selective weight loss. In obese non-human primates, two once-every-eight-week doses reduced visceral fat by 6.7% and total fat mass by 5.2% despite a high-calorie diet, with only a slight increase in lean mass.
These findings, consistent with prior rodent data and other Activin E–targeting approaches in human trials, support continued evaluation of IBIO-610 for obesity, cardiometabolic and cardiopulmonary diseases. iBio also highlighted strategic expansion into the cardiopulmonary field, including a myostatin x Activin A bispecific antibody program for pulmonary hypertension heart failure with preserved ejection fraction (PH-HFpEF), in an updated corporate presentation.
iBio, Inc. has filed a prospectus supplement to offer up to $100,000,000 of its common stock in an at-the-market offering through Jefferies LLC acting as sales agent.
Sales may occur from time to time under a Sales Agreement dated February 27, 2026, with commissions up to 3.0%. The prospectus states 34,543,561 shares outstanding as of February 24, 2026. Net proceeds, if any, are intended for working capital and general corporate purposes, including potential acquisitions, licensing, or repurchases.
iBio, Inc. entered into a new at-the-market stock offering program with Jefferies LLC, allowing sales of up to $100,000,000 of common stock under a new Form S-3 shelf registration statement, when declared effective. The company will control sale parameters such as timing, size per trading day, and minimum price, while paying Jefferies a commission of up to 3.0% of gross proceeds plus specified legal and filing-related fees.
iBio also terminated its prior at-the-market program with Chardan Capital Markets and Craig-Hallum Capital Group, which had permitted issuances of up to $7,350,000 of common stock. No further sales will occur under the prior agreement or its related prospectus.
iBio, Inc. filed a shelf registration on Form S-3 to offer up to $200,000,000 of securities, including up to $100,000,000 of Common Stock that may be offered under an Open Market Sales Agreement with Jefferies LLC dated February 27, 2026, to be sold from time to time as market conditions permit.
The prospectus states the offering may include Common Stock, Preferred Stock, debt securities, warrants or units. As context, the company reported 34,543,561 shares outstanding as of February 24, 2026 and 127,598,048 shares issuable upon exercise of outstanding warrants as of February 24, 2026.
iBio, Inc. received an updated Schedule 13G/A from ADAR1 Capital Management, related entities, and Daniel Schneeberger reporting beneficial ownership of up to 1,351,671 shares of common stock, or 4.4% of the company’s shares outstanding as of December 31, 2025.
The position includes 390,864 shares held by ADAR1 Partners, LP, smaller amounts in other managed accounts, and 956,140 shares underlying milestone warrants. The filers state the securities are held in the ordinary course of business and not for changing or influencing control, and they now report ownership of 5 percent or less of the class.
iBio, Inc. received an amended Schedule 13G filing showing that Logos Global Management LP and affiliated entities report beneficial ownership of 1,500,000 shares of iBio common stock. This stake represents 4.6% of the outstanding common shares, based on 32,540,942 shares outstanding as of January 30, 2026, as cited from iBio’s Form S-3.
The filing attributes the same 1,500,000-share, 4.6% position to Logos Global Management LP, Logos Global Management GP LLC, Logos Global Master Fund LP, Logos GP LLC, and Arsani William, with shared voting and dispositive power over all reported shares and no sole power. The reporting persons state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of iBio. They also jointly file while expressly disclaiming group status and beneficial ownership beyond their pecuniary interest.
iBio, Inc. received an amended Schedule 13G/A from Lynx1 Capital Management LP and Weston Nichols stating they no longer beneficially own any of the company’s common stock. The filing reports 0 shares beneficially owned and a 0% ownership stake, with no voting or dispositive power over any shares.
The reporting persons also certify that the securities referenced were not acquired and are not held for the purpose of changing or influencing control of iBio, Inc., and are not part of any control-related transaction.
iBio, Inc. reported a larger net loss while significantly strengthening its balance sheet as it advances its AI-driven obesity pipeline. For the three months ended December 31, 2025, the company generated no revenue, versus $200,000 a year earlier, and posted a net loss of $8.99 million as research and development and general and administrative expenses more than doubled.
For the six-month period, revenue was $100,000 and the net loss widened to $14.71 million. Operating cash outflows were $10.91 million, but financing activities, including sales of pre-funded warrants and common stock, provided $55.49 million, lifting cash and cash equivalents to $28.67 million and investments in debt securities to $24.03 million as of December 31, 2025.
The company recorded a $2.5 million impairment on an oncology intangible asset as it sharpened its focus on cardiometabolic and obesity antibodies. With approximately $52.7 million in cash and investments at period end and an additional $26 million raised in a January 2026 private placement, iBio believes it can fund operations for at least 12 months as it prepares IBIO-600 for Phase 1a trials in the first half of 2026 and targets first-in-human studies for IBIO-610 in early 2027.
iBio, Inc. reported a larger loss for its fiscal second quarter ended December 31, 2025 while strengthening its balance sheet and advancing its obesity-focused antibody pipeline. The company completed a $26 million private placement led by a biotech investor, receiving net proceeds of approximately $24.4 million in January 2026 and extending its cash runway into the third quarter of fiscal year 2028.
For the quarter, iBio recognized no revenue, compared with $0.2 million a year earlier. Research and development expenses rose to $4.3 million from $1.9 million, driven by higher spending on consultants, outside services, and personnel to progress IBIO-600, IBIO-610 and other preclinical assets. General and administrative expenses increased to approximately $5.2 million from $2.7 million, primarily due to an impairment of the IBIO-101 intangible asset, resulting in a net loss of $8,993 thousand versus $4,364 thousand.
iBio held $52.7 million in cash, cash equivalents and investments in debt securities as of December 31, 2025. Management highlighted initiation of CMC development and toxicology studies for IBIO-610 and IBIO-600 as key steps toward planned human clinical trials.